Lifeng Liu

Dr. Lifeng Liu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Materials Today Bio
Verified
Journal Article
Open access
XLX. Li
X. Li
HYH.J. Yuan
H.J. Yuan
XTX.M. Tian
X.M. Tian
JTJ. Tang
J. Tang
LLLifeng Liu
Lifeng Liu
FLFengyong Liu
Fengyong Liu
Transcatheter arterial embolization has been considered as a promising targeted delivery approach for hepatocellular carcinoma (HCC). Currently, chemoembolization was the main treatment for unresectable HCC. However, the traditional chemoembolization treatment suffers from undesirable therapeutic effects and serious side-effects. In this study, the doxorubicin (DOX)-encapsulated and near-infrared (NIR)–responsible copper sulfide (CuS)–based nanotherapeutics was developed for magnetic resonance imaging (MRI)–guided chemo-photothermal therapy of HCC tumor in rats. The DOX-loaded CuS nanocomposites (DOX@BSA-CuS) demonstrated distinct NIR-triggered drug release behavior and high photothermal effect. In an orthotopic HCC rat model, DOX@BSA-CuS nanocomposites were selectively delivered to the tumor site via the intra-arterial transcatheter. The proposed DOX@BSA-CuS nanocomposites plus NIR laser irradiation exhibited significant tumor growth suppression performance. Moreover, the treatment progress can be monitored by MRI images. Finally, the preliminary toxicity estimate suggested the negligible side-effect of DOX@BSA-CuS nanocomposites during the therapeutic process. These results suggest the clinical translational potential possibility for imaging-guided arterial embolization with DOX@BSA-CuS nanocomposites for the treatment of HCC.

5 December 2025 in Cancer Nanotechnology
Verified
Journal Article
Open access
PDF file
QCQiang Chen
Qiang Chen
YSYuqiang Shan
Yuqiang Shan
GYGuang Yin
Guang Yin
KCKangwen Cheng
Kangwen Cheng
HZHongzhu Zhang
Hongzhu Zhang
LLLifeng Liu
Lifeng Liu
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. Developing therapeutic approaches with a low recurrence rate, systemic toxici